ERBB2 and cancer: We evaluated CEM features of histopathologically confirmed cancers and analyzed their relationship with tumor subtype (grouped as luminal vs. HER2-enriched/triple-negative), alongside relevant clinical, imaging, and pathological variables (such as age, breast density, background parenchymal enhancement, and axillary nodal status).